Mycoplasma Testing Market Development Analysis, Share and Recent Trends By 2026 | Thermo Fisher Scientific Inc., Lonza Group Ltd., Merck KGaA, Roche Diagnostics, Bionique Testing Laboratories, Inc., InvivoGen

Market Size - USD 541.2 Million in 2018, Market Growth - CAGR of 12.6%, Market Trends - Growing awareness and cost and time effective diagnosis.

According to the current analysis of Reports and Data, the global Mycoplasma Testing market was valued at USD 541.2 million in 2018 and is expected to reach USD 1.42 million by year 2026, at a CAGR of 12.6%. Mycoplasma is the smallest discovered species of bacteria, mostly developed through the de-generative evolution from Gram-positive bacteria. Mycoplasma bacterial cell lacks a cell wall and can either be parasitic or saprotrophic. Though, there are around 200 different types of mycoplasma bacteria, most of them are harmless. Only 5 out of 200 cause severe infections in humans, which include Mycoplasma pneumonia, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum.

Avail the inside scoop of the Sample report @ https://www.reportsanddata.com/sample-enquiry-form/2129

Companies considered and profiled in this market study:
Thermo Fisher Scientific Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.), InvivoGen (U.S.), PromoCell GmbH (Germany), Norgen Biotek Corp. (Canada), GenBio (Canada), Meridian Bioscience, Inc. (U.S.), and Savyon Diagnostics (Israel).

Different species of mycoplasma cause different diseases in the human body. For example, Mycoplasma pneumonia affects the throat and lungs, while Mycoplasma genitalium is associated with urethra infection. Mycoplasma testing is used to diagnose present or past mycoplasma infection in patients. Mycoplasma microbes can exist as healthy flora in the patient's throat, genitourinary tract, or respiratory tract. Additionally, due to the lack of cell wall, the mycoplasma bacterial cells are immune to a several common antibiotics. Furthermore, mycoplasma testing plays an essential role in cell culture and must be done at every step of product development, including cell banks, viral seed stocks, and final products. The mycoplasma testing market is majorly driven by significant research and development activities in academia as well as the bio-pharmaceutical industry, increasing incidences of mycoplasma infections, and cell culture contamination.

Mycoplasma can quickly spread through droplets during cell culture and are difficult to detect under a microscope; hence, they need specific tests to be performed for the same. Growing expenditure in the healthcare sector by key market players to enhance customer satisfaction and achieve technological advancements is expected to propel the global market for mycoplasma testing.

Further key findings from the report suggest

o Mycoplasma testing market is growing at a CAGR of 13.0% in Asia Pacific, followed by North America and Europe, with 12.8 % and 12.5% CAGR respectively. Increasing government support, coupled with high investments in R&D, is a major factor driving the market growth.

o As of 2018, Kits & Reagents segment is the dominating Mycoplasma testing, which holds 47.5% of the global market. The Asia Pacific regional market is the chief revenue generating source for this product segment, followed by the North American and European regions.

o Mycoplasma infection is one of the major cause of human infectious diseases, therefore the sample requires to be tested at every step of processing.

Click here to avail the report at an unbelievable discount rate: https://www.reportsanddata.com/discount-enquiry-form/2129

o The absence of a cell wall allows the mycoplasma bacteria to enter the white blood corpuscles (WBCs), which makes it almost impossible to kill these bacteria once they hide in the immune system.

o As mycoplasma infection can become chronic, it reduces the efficiency and strength of the immune system, making it weak over time and highly increasing the risk of infections caused by other microorganisms.

For the purpose of this report, Reports and Data has segmented the mycoplasma testing market on the basis of product type, technology type, application type, end use, and region:

Product Type (Revenue, USD Million; 2016-2026)
o Instruments
o Kits & Reagents
o Services
o Others

Technology Type (Revenue, USD Million; 2016-2026)
o PCR
o ELISA
o Direct Assay
o Indirect Assay
o DNA Staining
o Microbial Culture Techniques
o Enzymatic Methods
o Others

Application Type (Revenue, USD Million; 2016-2026)
o Cell Line Testing
o Virus Testing
o End of Production Cells Testing
o Others

End Use (Revenue, USD Million; 2016-2026)
o Pharmaceutical Companies
o Cell Banks
o Others

Regional Outlook (Revenue in USD Million; 2016-2026)
o North America
o Europe
o Asia Pacific
o Middle East & Africa
o Latin America

Read the Comprehensive Report with a meticulous TOC and panoramic coverage of the market: https://www.reportsanddata.com/report-detail/mycoplasma-testing-market

Contact Us:

John Watson
Head of Business Development
Reports And Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.